Clik here to view.
C diff bacteria eaten by viruses
In the news: A possible scientific breakthrough in treating the Clostridium difficile bacterial infection: Researchers from the University of Leicester in England may have discovered a more potent, and...
View ArticleClik here to view.
Nation’s First Fecal Transplant Stool Sample Bank Opens
Grad students at MIT have created and started the Nation’s first stool sample bank. “Enter OpenBiome, which provides $250 samples to hospitals from screened patients, and has sent more than 135 such...
View ArticleClik here to view.
C. difficile treatment in clinical testing; Seres Health receives Notice of...
*In The News* Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has received a Notice of Allowance...
View ArticleClik here to view.
Rebiotix, Inc. PUNCH CD 2 Study – Second Clinical Trial Initiated
Update 24 November 2014 Rebiotix has initiated our second clinical trial (PUNCH CD 2) focusing on the treatment of recurrent C. difficile infection! REBIOTIX, INC. The PUNCH CD 2 study is a Phase 2B...
View ArticleClik here to view.
Lee Jones, Rebiotix and Glenn Taylor, Taymount Clinic Discuss Fecal...
Join us on Tuesday, April 7th at 11:00 a.m. Pacific / 2:00 p.m. Eastern Time As guests, Ms. Lee Jones, CEO Rebiotix, Inc. and Glenn Taylor, Microbiologist at Taymount Clinic discuss Fecal Microbiota...
View ArticleClik here to view.
Service Evaluation Study Data Shows DIFICLIR [TM] fidaxomicin by Astellas...
Presented May 20th, 2015 at the 5th International Clostridium Difficile Symposium (ICDS) in Bled, Slovenia, the CDI Service Evaluation Study is the first and only real-world multicenter study assessing...
View ArticleClik here to view.
Breaking News in Treatment of Recurrent C. difficile Infection : Rebiotix,...
Rebiotix Receives Breakthrough Therapy Designation for RBX2660 – A Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection Milestone reinforces Rebiotix as a...
View ArticleClik here to view.
AccessDIFICID (fidaxomicin) Is A Support Program For Patients Prescribed...
Dificid (fidaxomicin) Product Access and Support Information: AccessDIFICID is a support program for patients who have been prescribed DIFICID® (fidaxomicin) tablets. Case managers are available M-F,...
View ArticleClik here to view.
ZINPLAVA (bezlotoxumab) Is Now Available For Prescription To Reduce...
ZINPLAVA (bezlotoxumab) is now available for prescription. Ordering information is available on the brand website: http://www.zinplava.com/ What is Zinplava™ ? ZINPLAVA™ is indicated to reduce...
View ArticleCutisPharma Partners With C Diff Foundation To Support C.difficile Infection...
CutisPharma and the C Diff Foundation announced the launch of a partnership beginning on November 1, 2017, the first day of Clostridium difficile awareness month. As part of the partnership,...
View Article
